EU consults on future of project for accelerating trials in developing countries
This article was originally published in SRA
The European Commission is seeking feedback on the future of a research and development programme that was set up to accelerate the development of new and improved drugs against HIV/AIDS, malaria and tuberculosis. The programme’s current focus is on conducting Phase II and III clinical trials in Sub-Saharan Africa1,2.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.